Healthcare SPACs: The Biotech Body Count
Healthcare and biotech SPACs promised to revolutionize medicine: AI-powered diagnostics, telemedicine platforms, next-generation surgical tools, and genomics breakthroughs. The reality was grimmer. Healthcare SPACs had some of the worst outcomes of the entire SPAC boom, with an average loss of -84%. The sector combined the worst elements of SPAC structure with the worst elements of speculative biotech investing — and retail investors paid the price.
The Body Count
| Company | SPAC | Sector | Peak Valuation | Current Status | Return |
|---|---|---|---|---|---|
| Clover Health | SCH (Chamath) | Insurance/AI | $3.7B | $0.80/share | -92% |
| 23andMe | VG Acquisition | Genomics | $6.0B | Bankrupt | -99% |
| Butterfly Network | Longview | Medical Devices | $1.5B | $0.85/share | -91% |
| SOC Telemed | HCMC | Telemedicine | $720M | Acquired at -70% | -70% |
| Cano Health | JAWS Healthcare | Primary Care | $4.4B | Bankrupt | -99% |
| Hims & Hers | Oaktree | Telehealth | $1.6B | $55/share | +450% |
| Owlet | Sandbridge | Baby Health | $1.1B | $0.15/share | -99% |
| Nuvation Bio | Panbela (merged) | Oncology | $800M | $0.30/share | -97% |
Why Healthcare Was Especially Toxic
Healthcare companies are uniquely ill-suited for the SPAC model. Drug development takes 10-15 years and billions of dollars. Medical device approval requires years of clinical trials. Diagnostics companies need massive sales forces and payer relationships. These are not businesses that can be built with the $200-300M a SPAC trust provides — especially after redemptions drain most of that cash.
The SPAC structure's reliance on forward-looking projections was especially dangerous for healthcare. Biotech projections require assumptions about clinical trial success rates (historically ~10% for novel drugs), regulatory approval timelines, reimbursement rates, and market adoption — all of which are wildly uncertain. SPAC sponsors presented best-case scenarios as base cases, and retail investors who couldn't evaluate the science took the projections at face value.
Clover Health's deception: Clover Health, sponsored by Chamath Palihapitiya, merged at a $3.7B valuation while under undisclosed DOJ investigation. When short-seller Hindenburg Research revealed the investigation in February 2021, the stock initially rallied (driven by meme-stock traders) before collapsing 92%. Chamath had alreadysold his personal stake.
The 23andMe Catastrophe
23andMe's SPAC merger with VG Acquisition Corp (backed by Richard Branson) valued the genomics company at $6 billion. The pitch was compelling: 12 million DNA profiles, a therapeutics pipeline, and the promise of personalized medicine. The reality: DNA testing was a saturated consumer fad, the therapeutics pipeline was years from revenue, and the company burned through cash at an alarming rate.
By 2024, 23andMe was trading under $1. CEO Anne Wojcicki attempted a going-private transaction that the board rejected. The company filed for bankruptcy protection in early 2025, with 15 million customers' DNA data headed for potential sale to the highest bidder — a dystopian outcome that nobody envisioned when the SPAC merger was celebrated on CNBC.
The Lone Survivor: Hims & Hers
In a sea of healthcare SPAC disasters, one company stands out: Hims & Hers Health, which merged with Oaktree Acquisition Corp in 2021 at a $1.6B valuation. Unlike most healthcare SPACs, Hims had an established consumer brand, recurring revenue from subscription telehealth services, and a path to profitability that didn't depend on clinical trial outcomes or regulatory approvals. The stock fell initially post-merger but recovered dramatically, trading above $50 by early 2026.
What made Hims different:Revenue at merger ($149M annual run rate), a proven consumer brand, subscription-based recurring revenue, and no dependency on FDA approvals for core products. It was, in many ways, the least "biotech" of the healthcare SPACs — which is precisely why it survived.
Lessons from the Healthcare Wreckage
The healthcare SPAC disaster carries a clear lesson: early-stage, capital-intensive, science-dependent businesses should not go public via SPAC. They need patient capital, expert investors who understand clinical risk, and the freedom from quarterly earnings pressure that private markets provide. SPACs forced these companies into the public spotlight before they were ready — and public markets punished them mercilessly for not delivering on impossible projections.
Healthcare SPAC data from SEC filings, Evaluate Pharma, and SPACGraveyard tracking. Updated March 2026.